Sign in

You're signed outSign in or to get full access.

Susan Chor

Susan Chor

Research Analyst at Bank of America Corp. /de/

New York, NY, US

Susan Chor is an Equity Research Associate at Bank of America, covering the US Biopharmaceuticals sector with a particular focus on Large and SMid Cap Biotech and Major Pharma. Her company coverage includes Amylyx Pharmaceuticals Inc., as evidenced by her participation in analyst earnings calls, though performance track record metrics such as rankings or returns are not publicly available. Susan began her career prior to joining Bank of America but specific previous employers and full career timeline details are not disclosed. She supports senior analysts on the biotech and pharma research team, though there is no publicly available information on FINRA registration or securities licenses.

Susan Chor's questions to Amylyx Pharmaceuticals (AMLX) leadership

Question · Q2 2025

Susan Chor, on for Tim Anderson, asked about the risk of the event-driven LUCIDITY trial being delayed due to a lack of events and the assumptions underpinning the H1 2026 data readout timeline.

Answer

Chief Medical Officer Dr. Camille Bedrosian stated they do not anticipate event rates impacting the timeline, referencing the substantial event reductions seen in prior studies. Co-CEO & Co-Founder Josh Cohen reiterated the timeline, confirming enrollment completion is expected by year-end 2025, with data in H1 2026, as the timeline is driven by enrollment, not event rate.

Ask follow-up questions

Fintool

Fintool can predict Amylyx Pharmaceuticals logo AMLX's earnings beat/miss a week before the call